These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29285707)

  • 1. An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat.
    Becker KA; Jones JJ
    Adv Ther; 2018 Jan; 35(1):5-11. PubMed ID: 29285707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.
    Bailey CK; Caltabiano S; Cobitz AR; Huang C; Mahar KM; Patel VV
    BMC Nephrol; 2019 Oct; 20(1):372. PubMed ID: 31619187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.
    Tsubakihara Y; Akizawa T; Nangaku M; Onoue T; Yonekawa T; Matsushita H; Endo Y; Cobitz A
    Ther Apher Dial; 2020 Apr; 24(2):108-114. PubMed ID: 31306555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV;
    N Engl J Med; 2021 Dec; 385(25):2325-2335. PubMed ID: 34739194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat.
    Becker K; Saad M
    Adv Ther; 2017 Apr; 34(4):848-853. PubMed ID: 28290095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
    Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
    Singh AK; Carroll K; McMurray JJV; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; DiMino TL; Kler L; Meadowcroft AM; Taft L; Perkovic V;
    N Engl J Med; 2021 Dec; 385(25):2313-2324. PubMed ID: 34739196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Comparison between Vadadustat and Daprodustat Regarding Dose, Cost, and Safety of Treatment for Renal Anemia in Non-dialysis Patients with Chronic Kidney Diseases.
    Imai E; Imai A
    Intern Med; 2024 Jul; 63(13):1855-1861. PubMed ID: 37926547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients.
    Kanai H; Nangaku M; Nagai R; Okuda N; Kurata K; Nagakubo T; Endo Y; Cobitz A
    Ther Apher Dial; 2021 Dec; 25(6):979-987. PubMed ID: 33964183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis.
    Xie D; Wang J; Wu X; Li M
    Int Urol Nephrol; 2018 Dec; 50(12):2201-2206. PubMed ID: 30073615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of daprodustat for patients on dialysis with anemia: systematic review and network meta-analysis.
    Ali Fadlalmola H; Al-Sayaghi KM; Al-Hebshi AA; Alhujaily M; Alyamani AO; Alem AA; Syrafi MH; Alem S; Farhat AH; Mohamed FA; Abdalrahman HH; Abdelmalik MA; Abdalrhman NM; Eltayeb AM
    Pan Afr Med J; 2024; 47():114. PubMed ID: 38828426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study in Healthy Japanese Participants to Evaluate the Bioequivalence and the Food Effect on the Pharmacokinetics of Daprodustat.
    Yamada M; Osamura M; Ogura H; Onoue T; Wakamatsu A; Numachi Y; Caltabiano S; Mahar KM
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):978-984. PubMed ID: 32250021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial.
    Nangaku M; Hamano T; Akizawa T; Tsubakihara Y; Nagai R; Okuda N; Kurata K; Nagakubo T; Jones NP; Endo Y; Cobitz AR
    Am J Nephrol; 2021; 52(1):26-35. PubMed ID: 33561857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective Effects of Daprodustat in Patients with Chronic Kidney Disease and Renal Anemia.
    Shimada Y; Izumi Y; Yasuoka Y; Oshima T; Nagaba Y; Nanami M; Sands JM; Takahashi N; Kawahara K; Nonoguchi H
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia.
    Mahar KM; Yang S; Mesic E; Post TM; Goulooze SC
    Clin Pharmacokinet; 2024 Sep; 63(9):1327-1341. PubMed ID: 39259485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does HIF-PHI increased risk of gastrointestinal hemorrhage in patients with renal anemia: a review of cases reported to the U.S. Food and drug administration adverse event reporting system.
    Zhou Y; Ren Q; Hu R; Zheng K; Qin Y; Li X
    Ren Fail; 2021 Dec; 43(1):1170-1171. PubMed ID: 34315325
    [No Abstract]   [Full Text] [Related]  

  • 18. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
    Doggrell SA
    Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemistry, Analysis, and Biological Aspects of Daprodustat, A New Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor: A Comprehensive Review.
    Patil R; Sharma S
    Mini Rev Med Chem; 2024; 24(20):1847-1855. PubMed ID: 38685804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daprodustat (Jesduvroq) for anemia of chronic kidney disease.
    Med Lett Drugs Ther; 2024 Feb; 66(1696):25-27. PubMed ID: 38412265
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.